M. Laitinen et al., Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty, HUM GENE TH, 11(2), 2000, pp. 263-270
Blood vessels are among the easiest targets for gene therapy, However, no d
ata are available about the safety and feasibility of intracoronary gene tr
ansfer in humans. We studied the safety and efficacy of catheter-mediated v
ascular endothelial growth factor (VEGF) plasmid/liposome (P/L) gene transf
er in human coronary arteries after percutaneous translumenal coronary angi
oplasty (PTCA) in a randomized, double-blinded, placebo-controlled study. T
he optimized angioplasty/gene delivery method was previously shown to lead
to detectable VEGF gene expression in human peripheral arteries as analyzed
from amputated leg samples. Gene transfer to coronary arteries was done wi
th a perfusion-infusion catheter, using 1000 mu g of VEGF or beta-galactosi
dase plasmid complexed with 1000 mu l of DOTMA:DOPE liposomes, Ten patients
received VEGF P/L, three patients received beta-galactosidase P/L, and two
patients received Ringer lactate. Gene transfer to coronary arteries was f
easible and well tolerated. Except for a slight increase in serum C-reative
protein in all study groups, no adverse effects or abnormalities in labora
tory parameters were detected. No VEGF plasmid or recombinant VEGF protein
was present in the systemic circulation after the gene transfer. In control
angiography 6 months later, no differences were detected in the degree of
coronary stenosis between treatment and control groups. We conclude that ca
theter-mediated intracoronary gene transfer performed after angioplasty is
safe and well tolerated and potentially applicable for the prevention of re
stenosis and myocardial ischemia.